Please assess the completion status of the following clinical trial:

Trial Title: A Non-inferiority Study With Two Treatment Arms Eszopiclone 3 mg Versus Zopiclone 7.5 mg - for the Treatment of Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sign the informed consent form for the study;~* Be ≥ 20 to ≥ 64 years old;~* Have diagnosis of symptomatic primary insomnia for at least 3 months;~* Have polysomnography conducted at least 90 days before the inclusion in the study with sleep time less than 6.5 hours and sleep latency ≥ 20 minutes;~* Be able not to take any insomnia medication for 14 days before randomization to the study (washout period).~Exclusion Criteria:~* Diagnosis of other sleep disorder by polysomnography conducted 90 days before the inclusion in the study;~* Use of any medication affecting the sleep, such as psychotropic, hypnotic or antihistamine agents for at least 15 days before the inclusion in the study;~* Use of any herbal supplement for insomnia or melatonin during the 14 days before entering the study;~* Current use of liver metabolized medication, especially those metabolized through the cytochrome P450 enzyme complex, especially through the CYP3A4 and/or CYP2E1 routes;~* History of daily use of alcohol beverages in quantities equivalent - from the ethanol standpoint - to two cans of beer a day (35 g of alcohol/day);~* History of substance abuse or dependence;~* Patients with severe co-morbidities (at the investigator's opinion);~* Presence of liver disorders, cirrhosis or liver failure;~* Presence of psychiatric disorders diagnosed at the adult life or currently under treatment;~* Pregnant and breastfeeding women and women who want to become pregnant during the study period and who refuse to use a proper contraceptive methods during the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 64 Years
- Healthy Volunteers: f

Study Arms:
- eszopiclone 3 mg (Type: EXPERIMENTAL): Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
- zopiclone 7,5mg (Type: ACTIVE_COMPARATOR): Zopiclone once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)

Based on this trial design, predict the completion outcome and termination type (if applicable).